reclassify Marinol (dronabinol) from Schedule II to Schedule III

December 1998

The DEA is proposing to reclassify Marinol (dronabinol) from Schedule II to Schedule III.

Marinol is a synthetic form of THC...the active ingredient in marijuana. It's used for nausea or to improve appetite in patients with cancer or AIDS.

Marinol has a low potential for abuse. Its slow onset doesn't produce the same high that people get from smoking marijuana.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

new drugs coming out for rheumatoid arthritis
Infectious Diseases new precautions about hepatotoxicity with the new quinolone, Trovan (trovafloxacin)
Infectious Diseases surprising interaction between ORAL Trovan and IV morphine
new question about whether it might cause neurotoxicity
Interactions add carbamazepine (Tegretol) to the list of drugs that can interact with grapefruit juice
Interactions which anticonvulsants interact with hormonal contraceptives
Cardiology updated their guidelines for preventing stroke in patients with atrial fibrillation
Pediatrics Versed (midazolam) now comes as an ORAL syrup
Pediatrics Robi Comb to electronically "zap" head lice
Pediatrics Many parents of autistic kids are asking about secretin
Breast Cancer The National Cancer Institute is now offering "Risk Disk"
Substance Use Disorder people getting addicted to OTC stimulants
Substance Use Disorder first drug abuse test that can be performed AT HOME
Substance Use Disorder reclassify Marinol (dronabinol) from Schedule II to Schedule III
Asthma Pulmicort Turbuhaler (budesonide) is now approved for ONCE daily dosing
Neurology & Pain restricting the use of Tasmar (tolcapone) due to reports of serious hepatotoxicity
possible link between hepatitis B vaccination and autoimmune disorders
backlash from managed care against all the drug ads on TV, radio, magazines, etc

reclassify Marinol (dronabinol) from Schedule II to Schedule III

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents